- Live webcast to be held on November 15th at
12:00 p.m. EST –
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of refractory chronic cough
(“RCC”) and other hypersensitization-related disorders, today
announced that it will convene a virtual analyst event to discuss
the chronic cough landscape and its selective P2X3 antagonist,
BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.
The virtual event will feature presentations by Key Opinion
Leader (“KOL”) Sidney Braman, MD, Master FCCP, Professor Emeritus
of Medicine, Pulmonary, Critical Care and Sleep Medicine at the
Icahn School of Medicine at Mount Sinai, KOL Lorcan McGarvey, MD,
FRCP, Professor of Respiratory Medicine at Queen’s University
Belfast, and KOL Jacky Smith, MB, ChB, FRCP, PhD, Professor of
Respiratory Medicine at the University of Manchester and the
principal investigator of BELLUS Health’s Phase 2b SOOTHE trial.
The KOLs will discuss the unmet need in chronic cough, review
current therapies in development for RCC, including P2X3
antagonists, as well as review clinical evidence from the Phase 2a
RELIEF trial of BLU-5937 in RCC.
In preparation for the expected topline results for both its
Phase 2b SOOTHE trial in RCC and Phase 2a BLUEPRINT trial in
chronic pruritus associated with AD in December 2021, BELLUS Health
will also provide clinical development updates for BLU-5937 in RCC,
including Phase 3 program considerations, as well as discuss the
potential broad applicability of its P2X3 antagonist platform
across various hypersensitization-related disorders.
Event Details:
Event: BELLUS Health Virtual Analyst Event Date:
Monday, November 15, 2021 Time: 12:00 – 2:00 p.m. EST
The live webcast of the event may be accessed through the Events
& Presentations page of BELLUS Health’s website, under the
Investors & News section. The archived webcast and presentation
will be available on the Company’s website after the event.
About BLU-5937
BLU-5937, a highly selective P2X3 antagonist, is in development
for RCC, chronic pruritus and other hypersensitization-related
disorders.
The P2X3 receptor, which is implicated in cough reflex
hypersensitization, is a rational target for treating chronic
cough, and it has been evaluated in multiple clinical trials with
different P2X3 antagonists. The Company believes that its highly
selective P2X3 antagonist has the potential to reduce coughing in
patients with RCC, while limiting taste disturbance adverse
events.
In addition to RCC and chronic pruritus, the mechanism of
BLU-5937 may also have broad therapeutic applicability across other
afferent hypersensitization-related disorders, enabling the Company
to consider BLU-5937 as a potential treatment for a number of other
indications. Consequently, BELLUS Health is exploring how the P2X3
pathway may contribute to irritation and pain in a variety of
afferent hypersensitization-related disorders and whether
inhibition of P2X3 receptors can help treat these conditions.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of RCC and other
hypersensitization-related disorders. The Company's product
candidate, BLU-5937, is being developed for the treatment of adults
with RCC and chronic pruritus associated with atopic dermatitis
(“AD”).
RCC is a cough lasting more than 8 weeks despite appropriate
treatment for underlying condition(s). It is estimated that there
are approximately 9 million patients in the United States suffering
from RCC. RCC is associated with significant adverse physical,
social, and psychosocial effects on health and quality of life.
Currently, there is no specific therapy approved for RCC and
treatment options are limited.
Chronic pruritus associated with AD is an irritating sensation
that leads to scratching and persists for longer than 6 weeks in AD
patients. It is estimated that up to 10% of adults in the United
States suffer from AD – almost all report symptoms of pruritus with
over 50% of patients attributing chronic pruritus as their most
burdensome symptom. Despite currently available treatments
targeting AD, there continues to be a lack of options specifically
targeting the burden of pruritus in patients with AD.
Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations, the
U.S. Private Securities Litigation Reform Act of 1995, as amended,
and other applicable securities laws. Forward-looking statements
are frequently, but not always, identified by words such as
“expects,” “anticipates,” “believes,” “intends,” “estimates,”
“potential,” “possible,” “projects,” “plans,” and similar
expressions. Such statements, based as they are on the current
expectations of management, inherently involve numerous important
risks, uncertainties and assumptions, known and unknown, many of
which are beyond BELLUS Health's control. Such statements include,
but are not limited to, the potential of BLU-5937 to successfully
treat RCC, chronic pruritus associated with AD and other
hypersensitization-related disorders, BELLUS Health’s expectations
related to its preclinical studies and clinical trials, including
the design, timing and results of its Phase 2b clinical trial of
BLU-5937 in RCC and its Phase 2a clinical trial of BLU-5937 in
chronic pruritus associated with AD, including the timing and
outcome of interactions with regulatory agencies, the potential
activity and tolerability profile, selectivity, potency and other
characteristics of BLU-5937, including as compared to other
competitor candidates, the commercial potential of BLU-5937,
including with respect to patient population, pricing and labeling,
BELLUS Health’s financial position, and the potential applicability
of BLU-5937 and BELLUS Health’s P2X3 platform to treat other
disorders. Risk factors that may affect BELLUS Health’s future
results include but are not limited to: the benefits and impact on
label of its enrichment strategy, estimates and projections
regarding the size and opportunity of the addressable RCC market
for BLU-5937, the ability to expand and develop its project
pipeline, the ability to obtain adequate financing, the ability of
BELLUS Health to maintain its rights to intellectual property and
obtain adequate protection of future products through such
intellectual property, the impact of general economic conditions,
general conditions in the pharmaceutical industry, the impact of
the ongoing COVID-19 pandemic on BELLUS Health’s operations, plans
and prospects, including to the initiation and completion of
clinical trials in a timely manner or at all, changes in the
regulatory environment in the jurisdictions in which BELLUS Health
does business, supply chain impacts, stock market volatility,
fluctuations in costs, changes to the competitive environment due
to consolidation, achievement of forecasted burn rate, potential
payments/outcomes in relation to indemnity agreements and
contingent value rights , achievement of forecasted preclinical
study and clinical trial milestones, reliance on third parties to
conduct preclinical studies and clinical trials for BLU-5937 and
that actual results may vary once the final and quality-controlled
verification of data and analyses has been completed. In addition,
the length of BELLUS Health’s product candidate’s development
process and its market size and commercial value are dependent upon
a number of factors. Moreover, BELLUS Health’s growth and future
prospects are mainly dependent on the successful development,
patient tolerability, regulatory approval, commercialization and
market acceptance of its product candidate BLU-5937 and other
products. Consequently, actual future results and events may differ
materially from the anticipated results and events expressed in the
forward-looking statements. BELLUS Health believes that
expectations represented by forward-looking statements are
reasonable, yet there can be no assurance that such expectations
will prove to be correct. The reader should not place undue
reliance, if any, on any forward-looking statements included in
this news release. These forward-looking statements speak only as
of the date made, and BELLUS Health is under no obligation and
disavows any intention to update publicly or revise such statements
as a result of any new information, future event, circumstances or
otherwise, unless required by applicable legislation or regulation.
Please see BELLUS Health's public filings with the Canadian
securities regulatory authorities, including, but not limited to,
its Annual Information Form, and the United States Securities and
Exchange Commission, including, but not limited to, its Annual
Report on Form 40-F, for further risk factors that might affect
BELLUS Health and its business.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211101005333/en/
FOR MORE INFORMATION: Ramzi Benamar Chief Financial
Officer rbenamar@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
Immucor, Inc. (MM) (NASDAQ:BLUD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immucor, Inc. (MM) (NASDAQ:BLUD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024